Cargando…
Cellular and Genetic Background of Osteosarcoma
Osteosarcoma describes a tumor of mesenchymal origin with an annual incidence rate of four to five people per million. Even though chemotherapy treatment has shown success in non-metastatic osteosarcoma, metastatic disease still has a low survival rate of 20%. A targeted therapy approach is limited...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217763/ https://www.ncbi.nlm.nih.gov/pubmed/37232745 http://dx.doi.org/10.3390/cimb45050276 |
_version_ | 1785048616115634176 |
---|---|
author | Urlić, Inga Jovičić, Marijana Šimić Ostojić, Karla Ivković, Alan |
author_facet | Urlić, Inga Jovičić, Marijana Šimić Ostojić, Karla Ivković, Alan |
author_sort | Urlić, Inga |
collection | PubMed |
description | Osteosarcoma describes a tumor of mesenchymal origin with an annual incidence rate of four to five people per million. Even though chemotherapy treatment has shown success in non-metastatic osteosarcoma, metastatic disease still has a low survival rate of 20%. A targeted therapy approach is limited due to high heterogeneity of tumors, and different underlying mutations. In this review, we will summarize new advances obtained by new technologies, such as next generation sequencing and single-cell sequencing. These new techniques have enabled better assessment of cell populations within osteosarcoma, as well as an understanding of the molecular pathogenesis. We also discuss the presence and properties of osteosarcoma stem cells—the cell population within the tumor that is responsible for metastasis, recurrence, and drug resistance. |
format | Online Article Text |
id | pubmed-10217763 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102177632023-05-27 Cellular and Genetic Background of Osteosarcoma Urlić, Inga Jovičić, Marijana Šimić Ostojić, Karla Ivković, Alan Curr Issues Mol Biol Review Osteosarcoma describes a tumor of mesenchymal origin with an annual incidence rate of four to five people per million. Even though chemotherapy treatment has shown success in non-metastatic osteosarcoma, metastatic disease still has a low survival rate of 20%. A targeted therapy approach is limited due to high heterogeneity of tumors, and different underlying mutations. In this review, we will summarize new advances obtained by new technologies, such as next generation sequencing and single-cell sequencing. These new techniques have enabled better assessment of cell populations within osteosarcoma, as well as an understanding of the molecular pathogenesis. We also discuss the presence and properties of osteosarcoma stem cells—the cell population within the tumor that is responsible for metastasis, recurrence, and drug resistance. MDPI 2023-05-15 /pmc/articles/PMC10217763/ /pubmed/37232745 http://dx.doi.org/10.3390/cimb45050276 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Urlić, Inga Jovičić, Marijana Šimić Ostojić, Karla Ivković, Alan Cellular and Genetic Background of Osteosarcoma |
title | Cellular and Genetic Background of Osteosarcoma |
title_full | Cellular and Genetic Background of Osteosarcoma |
title_fullStr | Cellular and Genetic Background of Osteosarcoma |
title_full_unstemmed | Cellular and Genetic Background of Osteosarcoma |
title_short | Cellular and Genetic Background of Osteosarcoma |
title_sort | cellular and genetic background of osteosarcoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217763/ https://www.ncbi.nlm.nih.gov/pubmed/37232745 http://dx.doi.org/10.3390/cimb45050276 |
work_keys_str_mv | AT urlicinga cellularandgeneticbackgroundofosteosarcoma AT jovicicmarijanasimic cellularandgeneticbackgroundofosteosarcoma AT ostojickarla cellularandgeneticbackgroundofosteosarcoma AT ivkovicalan cellularandgeneticbackgroundofosteosarcoma |